From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO – SKIN CANCER
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in skin cancer
Prof Dr Jean-François Baurain, a medical oncologist at the Cliniques Universitaires Saint-Luc, Brussels presents an update on advanced melanoma from ASCO.
An updated analysis of the RELATIVITY-047 trial, which
Dr Iris Dirven, medical oncologist in training at the University Hospital of Brussels discussed her selection from the rapid oral abstract session on melanoma/skin cancer.
The NADOM trial investigated
Prof Dr Jean-François Baurain, a medical oncologist at the Cliniques Universitaires Saint-Luc, Brussels presents a first selection of interesting highlights in melanoma and skin cancer.
The COMBI-AD study assessed
In-depth stories about skin cancer
At ASCO, Prof Jeffrey Weber presented the 3-year update of the KEYNOTE-942 trial. mRNA-4157 is an innovative, mRNA-based individualized neoantigen therapy designed to enhance endogenous antitumor T-cell responses by targeting
Based on the results of CheckMate-067 and RELATIVITY-047, the combination of nivolumab with either ipilimumab or relatlimab (anti LAG-3) gained approval as first line treatment options for patients with advanced
In recent years, several studies have evaluated the optimal treatment sequence in patients with BRAF-mutated advanced melanoma. These studies concluded that immunotherapy first, followed by targeted therapy is preferred when
Prof Dr Christian Blank, a medical oncologist at the Netherlands Cancer Institute, presented the first data from the NADINA trial at the ASCO 2024 plenary session.
This investigator-initiated trial
Melanoma poster skin cancer
Dr Iris Dirven, a medical oncologist in training at the University Hospital of Brussels, summarized the main efficacy and safety outcomes of an indirect treatment comparison between first-line nivolumab plus
Dr Iris Dirven, a medical oncologist in training, and Prof Bart Neyns, a medical oncologist at the University Hospital of Brussels, reported promising results from their research in the RegoMel
Prof Jean-François Baurain, Cliniques Universitaires Saint-Luc, Brussels gave a concise summary of the LEAP-004 study. With over four years of follow-up, lenvatinib in combination with pembrolizumab continued to demonstrate antitumor